Additionally, individuals with mutations in PTPN11, particularly those with germline pathogenic variants in codons 61, 71, 72, and 76, are at risk for juvenile myelomonocytic leukemia (JMML), and patients with HRAS mutations have a significantly increased risk of malignancy even compared to other RASopathies (101, 174). This evidence concerns the gene PTPN11 and juvenile myelomonocytic leukemia.